Covid Vaccine Race

The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.

People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.

If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.

Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.

The booster is designed for immunization against the original wild strain as well as Omicron variant.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

This study looks to identify safety, efficacy of the vaccine in the youngest pediatric populations.

The modified spike protein in this next-generation bivalent candidate is part of the companies' strategy to try and provide vaccines with longer and more durable protection against the virus.

Omicron-specific vaccine boosters are coming, but just how necessary are they?

Clinicians offer insights on a variety of elements surrounding boosters.

As the pandemic enters its third year, fatigue and frustration grow, but there is hope for the future.

He is experiencing mild symptoms and is going to take Paxlovid.

This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.

The European agency says there have been “a few cases of anaphylaxis.” The label will also include warnings for paraesthesia and hypoaesthesia.

There has been an increase in transmission rates, the release of new White House strategies to address BA.5, and new potential offerings to prevent and treat the virus.

The federal agency says it is indicated as a two-dose primary series for active immunization to prevent the virus in individuals 18 years of age and over.

Receiving a COVID-19 booster vaccine significantly reduced Omicron infections among National Basketball Association (NBA) players and staff.

The company’s investigational mRNA-1273.214 vaccine has now demonstrated significantly higher antibody titers against all tested variants.

Health care workers in Italy infected with SARS-CoV-2 were less likely to develop long COVID symptoms if they were fully vaccinated and boosted with an mRNA vaccine, a recent study found.

Here is a rundown of the most popular and significant stories we covered this past week.

Antibody levels decline in individuals with hybrid immunity similarly to vaccinated individuals, meaning all people need a booster vaccine to protect against future, potentially severe, infection.

A computational framework for estimating vaccine effectiveness based on genetic differences of SARS-CoV-2 variants showed promising results in a new study that verified the model with clinical trial data.

After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.

Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.

Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.

Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.

Studies, advances, and authorizations continue in this paramount area within infectious disease.